Acquisition by Kama Gulsen of 16000 shares of Bionano Genomics subject to Rule 16b-3

Read at macroaxis.com

Published over six months ago View all stories for Bionano Genomics | Bionano Genomics Hype Analysis

Bionano insider trading alert for acquisition of common stock by Kama Gulsen, Officer: Chief Financial Officer, on 19th of October 2024. This event was filed by Bionano Genomics with SEC on 2024-06-03. Statement of changes in beneficial ownership - SEC Form 4

We analyze Bionano Genomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionano Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionano Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bionano Genomics stock to make a market-neutral strategy. Peer analysis of Bionano Genomics could also be used in its relative valuation, which is a method of valuing Bionano Genomics by comparing valuation metrics with similar companies.

Check out Bionano Genomics Hype Analysis, Bionano Genomics Correlation and Bionano Genomics Performance. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.